GLP1-RA, Kidney Disease
Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...
New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.
The GLP-1 drug, exenatide ... to patients affected by Parkinson's disease and the Parkinson's disease research community." GLP-1 drugs—such as semaglutide (Wegovy) and Ozempic—have become ...
They're known to aid in blood sugar control and, now, weight loss — however, according to a sweeping new study, the popular ...
Treatment with the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide had no disease-modifying effects on movement, symptom severity or brain imaging in patients with Parkinson’s ...
News Medical on MSN10d
Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugsObesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...
Previous studies suggest GLP-1 receptor agonists may benefit those with Parkinson’s disease. A phase 3 randomized controlled trial found no significant improvements with the GLP-1 exenatide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback